Reading the tape
NYSE: BDX
Becton, Dickinson and Company
Healthcare · Medical - Instruments & Supplies
Market Cap
$54.09B
52w High
$187.35
52w Low
$127.59
P/E
24.23
Volume
1.82M
Outstanding Shares
362.30M
Valuation Data Insufficient
The DCF model's fair value estimate is more than 3× the current stock price. This typically indicates unreliable model inputs — such as irregular cash flows or balance sheet distortions — rather than a genuine opportunity, so the valuation is not shown.
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 42.48%Revenue (TTM): 6.22%FCF (TTM): -10.39%P/FCF: 49th pct
What changed
The stock rose 42.48% over the last year. Revenue grew 6.22% over the trailing twelve months. Operating margin moved from 11.68% to 12.4%. Free cash flow declined 10.39% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 12.4%. A decisive move in revenue — currently up 6.22% — would be the clearest signal to resolve the ambiguity.
Company profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
CEOThomas E. Polen Jr.
SectorHealthcare
IndustryMedical - Instruments & Supplies
Employees70,000
IPO dateFeb 21, 1973
Valuation
Forward P/E—
EV/EBITDA10.39
Enterprise value$51.49B
Stock splits
Feb 10, 2026↑ Forward
Every 125 shares became 159
Apr 1, 2022↑ Forward
Every 40 shares became 41
Aug 21, 1998↑ Forward
Every 1 shares became 2
Aug 16, 1996↑ Forward
Every 1 shares became 2
Mar 1, 1993↑ Forward
Every 1 shares became 2
Mar 3, 1986↑ Forward
Every 1 shares became 2
Profitability & growth
Revenue growth1.63%
Gross margin45.76%▲0.48%vs FY2024
Operating margin12.4%▼0.63%vs FY2024
ROE6.61%▲0.35%vs FY2024
Analyst consensus
RatingBuy
Target price$172.85▲15.77%
16
Buy
16
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est $2.77 · Revenue est $4.67B
View
Dividends
$3.74/shareQuarterlyDividend Aristocrat · 42yrAdequateBDX pays a dividend with a 2.51% declared yield, 42 consecutive years of growth, growing at 8.27% annually, covered 2.2× by free cash flow.
Declared Yield
2.51%
Annual Div / Share
$3.74
5yr CAGR
+8.27%
Doubles every ~8.7yr
Payout Ratio
67.9%
Adequate
Dividend Growth Rate
3yr CAGR
+9.76%
5yr CAGR
+8.27%
10yr CAGR
+6.58%
Dividend Safety
7/10Adequate
Dividend History
Annualized dividend cycles per share
YearAnnual DivYoY
2026$3.74+3.3%
2025$3.62+22.6%
2024$2.96+4.4%
2023$2.83+6.6%
2022$2.66+5.5%
2021$2.52+4.5%
2020$2.41+2.6%
Income Projection
Invest
$
Growth rate:
Reinvest dividends
Today
$25/yr
$2/mo
In 5 yrs
$37/yr+49%
$3/mo
In 10 yrs
$55/yr+121%
$5/mo
| Today | In 5 yrs | In 10 yrs |
|---|---|---|
$25/yr $2/mo | $37/yr+49% $3/mo | $55/yr+121% $5/mo |
Yield-on-cost grows from 2.51% → 5.55% over 10yr
Analysis
Dividend Strengths
Dividend Aristocrat
BDX has raised its dividend for 42 consecutive years — qualifying as a Dividend Aristocrat, demonstrating long-term commitment to shareholder income.
Well-covered by free cash flow
The dividend is covered 2.2× by free cash flow, indicating the company generates sufficient cash to sustain and potentially grow the payout without straining its finances.
Strong dividend growth rate
The 5-year CAGR of 8.27% meaningfully outpaces inflation, compounding real income growth for long-term holders.
Risks to Watch
No strong risk signal stands out from the latest period pair.
Congressional Activity
Congress Trades in BDX
STOCK Act disclosures from senators and representatives.
Kevin Hern
OKhouseRepublicanSaleJoint2026-03-17$15,001 - $50,000+20d to disclose